{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T14:40:14Z","timestamp":1735396814150,"version":"3.32.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-80837-w","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T01:23:25Z","timestamp":1735349005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A multiparametric screen uncovers FDA-approved small molecules that potentiate the nuclear mechano-dysfunctions in ATR-defective cells"],"prefix":"10.1038","volume":"14","author":[{"given":"Maria Rosaria","family":"Cera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Bastianello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Purushothaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Andronache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Ascione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Robusto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Fag\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Pasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Meroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingsen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramveer","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Varasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Foiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciro","family":"Mercurio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"80837_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrm2894","volume":"11","author":"K Mekhail","year":"2010","unstructured":"Mekhail, K. & Moazed, D. The nuclear envelope in genome organization, expression and stability. Nat. Rev. Mol. Cell Biol. 11, 317\u2013328. https:\/\/doi.org\/10.1038\/nrm2894 (2010).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"80837_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2023.102222","volume":"84","author":"G Bastianello","year":"2023","unstructured":"Bastianello, G. & Foiani, M. Mechanisms controlling the mechanical properties of the nuclei. Curr. Opin. Cell Biol. 84, 102222. https:\/\/doi.org\/10.1016\/j.ceb.2023.102222 (2023).","journal-title":"Curr. Opin. Cell Biol."},{"key":"80837_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ceb.2021.07.008","volume":"72","author":"GPF Nader","year":"2021","unstructured":"Nader, G. P. F., Williart, A. & Piel, M. Nuclear deformations, from signaling to perturbation and damage. Curr. Opin. Cell Biol. 72, 137\u2013145. https:\/\/doi.org\/10.1016\/j.ceb.2021.07.008 (2021).","journal-title":"Curr. Opin. Cell Biol."},{"key":"80837_CR4","doi-asserted-by":"publisher","first-page":"R1113","DOI":"10.1016\/j.cub.2013.11.009","volume":"23","author":"P Isermann","year":"2013","unstructured":"Isermann, P. & Lammerding, J. Nuclear mechanics and mechanotransduction in health and disease. Curr. Biol. 23, R1113-1121. https:\/\/doi.org\/10.1016\/j.cub.2013.11.009 (2013).","journal-title":"Curr. Biol."},{"key":"80837_CR5","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1038\/s41467-020-18580-9","volume":"11","author":"GR Kidiyoor","year":"2020","unstructured":"Kidiyoor, G. R. et al. ATR is essential for preservation of cell mechanics and nuclear integrity during interstitial migration. Nat. Commun. 11, 4828. https:\/\/doi.org\/10.1038\/s41467-020-18580-9 (2020).","journal-title":"Nat. Commun."},{"key":"80837_CR6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cell.2014.05.046","volume":"158","author":"A Kumar","year":"2014","unstructured":"Kumar, A. et al. ATR mediates a checkpoint at the nuclear envelope in response to mechanical stress. Cell 158, 633\u2013646. https:\/\/doi.org\/10.1016\/j.cell.2014.05.046 (2014).","journal-title":"Cell"},{"key":"80837_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.dnarep.2016.05.020","volume":"44","author":"GR Kidiyoor","year":"2016","unstructured":"Kidiyoor, G. R., Kumar, A. & Foiani, M. ATR-mediated regulation of nuclear and cellular plasticity. DNA Repair (Amst.) 44, 143\u2013150. https:\/\/doi.org\/10.1016\/j.dnarep.2016.05.020 (2016).","journal-title":"DNA Repair (Amst.)"},{"key":"80837_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrm2351","volume":"9","author":"D Branzei","year":"2008","unstructured":"Branzei, D. & Foiani, M. Regulation of DNA repair throughout the cell cycle. Nat. Rev. Mol. Cell Biol. 9, 297\u2013308. https:\/\/doi.org\/10.1038\/nrm2351 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"80837_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1101\/gad.14.4.397","volume":"14","author":"EJ Brown","year":"2000","unstructured":"Brown, E. J. & Baltimore, D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 14, 397\u2013402 (2000).","journal-title":"Genes Dev."},{"key":"80837_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1101\/gad.452308","volume":"22","author":"LI Toledo","year":"2008","unstructured":"Toledo, L. I., Murga, M., Gutierrez-Martinez, P., Soria, R. & Fernandez-Capetillo, O. ATR signaling can drive cells into senescence in the absence of DNA breaks. Genes Dev. 22, 297\u2013302. https:\/\/doi.org\/10.1101\/gad.452308 (2008).","journal-title":"Genes Dev."},{"key":"80837_CR11","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","volume":"21","author":"LM Karnitz","year":"2015","unstructured":"Karnitz, L. M. & Zou, L. Molecular pathways: Targeting ATR in cancer therapy. Clin. Cancer Res. 21, 4780\u20134785. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0479 (2015).","journal-title":"Clin. Cancer Res."},{"key":"80837_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1172\/JCI58928","volume":"122","author":"DW Schoppy","year":"2012","unstructured":"Schoppy, D. W. et al. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J. Clin. Invest. 122, 241\u2013252. https:\/\/doi.org\/10.1172\/JCI58928 (2012).","journal-title":"J. Clin. Invest."},{"key":"80837_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/ng1129","volume":"33","author":"M O'Driscoll","year":"2003","unstructured":"O\u2019Driscoll, M., Ruiz-Perez, V. L., Woods, C. G., Jeggo, P. A. & Goodship, J. A. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat. Genet. 33, 497\u2013501. https:\/\/doi.org\/10.1038\/ng1129 (2003).","journal-title":"Nat. Genet."},{"key":"80837_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.aad7297","volume":"352","author":"CM Denais","year":"2016","unstructured":"Denais, C. M. et al. Nuclear envelope rupture and repair during cancer cell migration. Science 352, 353\u2013358. https:\/\/doi.org\/10.1126\/science.aad7297 (2016).","journal-title":"Science"},{"key":"80837_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1126\/science.aad7611","volume":"352","author":"M Raab","year":"2016","unstructured":"Raab, M. et al. ESCRT III repairs nuclear envelope ruptures during cell migration to limit DNA damage and cell death. Science 352, 359\u2013362. https:\/\/doi.org\/10.1126\/science.aad7611 (2016).","journal-title":"Science"},{"key":"80837_CR16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1083\/jcb.201308029","volume":"204","author":"T Harada","year":"2014","unstructured":"Harada, T. et al. Nuclear lamin stiffness is a barrier to 3D migration, but softness can limit survival. J. Cell Biol. 204, 669\u2013682. https:\/\/doi.org\/10.1083\/jcb.201308029 (2014).","journal-title":"J. Cell Biol."},{"key":"80837_CR17","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson, N. & Ablasser, A. The cGAS-STING pathway and cancer. Nat. Cancer 3, 1452\u20131463. https:\/\/doi.org\/10.1038\/s43018-022-00468-w (2022).","journal-title":"Nat. Cancer"},{"key":"80837_CR18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1126\/science.1108297","volume":"308","author":"JH Lee","year":"2005","unstructured":"Lee, J. H. & Paull, T. T. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 308, 551\u2013554. https:\/\/doi.org\/10.1126\/science.1108297 (2005).","journal-title":"Science"},{"key":"80837_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford, A. N. & Jackson, S. P. ATM, ATR, and DNA-PK: The trinity at the heart of the DNA damage response. Mol. Cell 66, 801\u2013817. https:\/\/doi.org\/10.1016\/j.molcel.2017.05.015 (2017).","journal-title":"Mol. Cell"},{"key":"80837_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/s0092-8674(03)00033-3","volume":"112","author":"J Perry","year":"2003","unstructured":"Perry, J. & Kleckner, N. The ATRs, ATMs, and TORs are giant HEAT repeat proteins. Cell 112, 151\u2013155. https:\/\/doi.org\/10.1016\/s0092-8674(03)00033-3 (2003).","journal-title":"Cell"},{"key":"80837_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113555","volume":"42","author":"G Bastianello","year":"2023","unstructured":"Bastianello, G. et al. Cell stretching activates an ATM mechano-transduction pathway that remodels cytoskeleton and chromatin. Cell Rep. 42, 113555. https:\/\/doi.org\/10.1016\/j.celrep.2023.113555 (2023).","journal-title":"Cell Rep."},{"key":"80837_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.564601","volume":"8","author":"M Rose","year":"2020","unstructured":"Rose, M., Burgess, J. T., O\u2019Byrne, K., Richard, D. J. & Bolderson, E. PARP inhibitors: Clinical relevance, mechanisms of action and tumor resistance. Front. Cell Dev. Biol. 8, 564601. https:\/\/doi.org\/10.3389\/fcell.2020.564601 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"80837_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","volume":"376","author":"MW Audeh","year":"2010","unstructured":"Audeh, M. W. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 376, 245\u2013251. https:\/\/doi.org\/10.1016\/S0140-6736(10)60893-8 (2010).","journal-title":"Lancet"},{"key":"80837_CR24","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon, K. A. et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12, 852\u2013861. https:\/\/doi.org\/10.1016\/S1470-2045(11)70214-5 (2011).","journal-title":"Lancet Oncol."},{"key":"80837_CR25","doi-asserted-by":"publisher","first-page":"14086","DOI":"10.1038\/srep14086","volume":"5","author":"IT Bijsmans","year":"2015","unstructured":"Bijsmans, I. T. et al. The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression. Sci. Rep. 5, 14086. https:\/\/doi.org\/10.1038\/srep14086 (2015).","journal-title":"Sci. Rep."},{"key":"80837_CR26","doi-asserted-by":"publisher","first-page":"6607","DOI":"10.1038\/s41467-021-26935-z","volume":"12","author":"IH Kaltheuner","year":"2021","unstructured":"Kaltheuner, I. H. et al. Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation. Nat. Commun. 12, 6607. https:\/\/doi.org\/10.1038\/s41467-021-26935-z (2021).","journal-title":"Nat. Commun."},{"key":"80837_CR27","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","volume":"22","author":"S Goel","year":"2022","unstructured":"Goel, S., Bergholz, J. S. & Zhao, J. J. Targeting CDK4 and CDK6 in cancer. Nat. Rev. Cancer 22, 356\u2013372. https:\/\/doi.org\/10.1038\/s41568-022-00456-3 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"80837_CR28","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/nrd2132","volume":"5","author":"P Imming","year":"2006","unstructured":"Imming, P., Sinning, C. & Meyer, A. Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 5, 821\u2013834. https:\/\/doi.org\/10.1038\/nrd2132 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"80837_CR29","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","volume":"30","author":"DL Deremer","year":"2008","unstructured":"Deremer, D. L., Ustun, C. & Natarajan, K. Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin. Ther. 30, 1956\u20131975. https:\/\/doi.org\/10.1016\/j.clinthera.2008.11.014 (2008).","journal-title":"Clin. Ther."},{"key":"80837_CR30","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1177\/1060028013503124","volume":"47","author":"L Stansfield","year":"2013","unstructured":"Stansfield, L., Hughes, T. E. & Walsh-Chocolaad, T. L. Bosutinib: A second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia. Ann. Pharmacother. 47, 1703\u20131711. https:\/\/doi.org\/10.1177\/1060028013503124 (2013).","journal-title":"Ann. Pharmacother."},{"key":"80837_CR31","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","volume":"18","author":"J Mascarenhas","year":"2012","unstructured":"Mascarenhas, J. & Hoffman, R. Ruxolitinib: The first FDA approved therapy for the treatment of myelofibrosis. Clin. Cancer Res. 18, 3008\u20133014. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3145 (2012).","journal-title":"Clin. Cancer Res."},{"key":"80837_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2020.100838","volume":"24","author":"M Fischer","year":"2020","unstructured":"Fischer, M., Luck, M., Werle, M., Scheidt, H. A. & Muller, P. Binding of the small-molecule kinase inhibitor ruxolitinib to membranes does not disturb membrane integrity. Biochem. Biophys. Rep. 24, 100838. https:\/\/doi.org\/10.1016\/j.bbrep.2020.100838 (2020).","journal-title":"Biochem. Biophys. Rep."},{"key":"80837_CR33","doi-asserted-by":"publisher","first-page":"pgac270","DOI":"10.1093\/pnasnexus\/pgac270","volume":"2","author":"I Aifuwa","year":"2023","unstructured":"Aifuwa, I. et al. Senescent stroma induces nuclear deformations in cancer cells via the inhibition of RhoA\/ROCK\/myosin II-based cytoskeletal tension. PNAS Nexus 2, pgac270. https:\/\/doi.org\/10.1093\/pnasnexus\/pgac270 (2023).","journal-title":"PNAS Nexus"},{"key":"80837_CR34","doi-asserted-by":"publisher","first-page":"19017","DOI":"10.1073\/pnas.0908686106","volume":"106","author":"SB Khatau","year":"2009","unstructured":"Khatau, S. B. et al. A perinuclear actin cap regulates nuclear shape. Proc. Natl. Acad. Sci. USA 106, 19017\u201319022. https:\/\/doi.org\/10.1073\/pnas.0908686106 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"80837_CR35","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1038\/s41467-017-02217-5","volume":"8","author":"JK Kim","year":"2017","unstructured":"Kim, J. K. et al. Nuclear lamin A\/C harnesses the perinuclear apical actin cables to protect nuclear morphology. Nat. Commun. 8, 2123. https:\/\/doi.org\/10.1038\/s41467-017-02217-5 (2017).","journal-title":"Nat. Commun."},{"key":"80837_CR36","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1042\/CS20150149","volume":"129","author":"U Saran","year":"2015","unstructured":"Saran, U., Foti, M. & Dufour, J. F. Cellular and molecular effects of the mTOR inhibitor everolimus. Clin. Sci. (Lond.) 129, 895\u2013914. https:\/\/doi.org\/10.1042\/CS20150149 (2015).","journal-title":"Clin. Sci. (Lond.)"},{"key":"80837_CR37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1365-2133.2007.07975.x","volume":"157","author":"R Gniadecki","year":"2007","unstructured":"Gniadecki, R. et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br. J. Dermatol. 157, 433\u2013440. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07975.x (2007).","journal-title":"Br. J. Dermatol."},{"key":"80837_CR38","doi-asserted-by":"publisher","first-page":"29914","DOI":"10.18632\/oncotarget.4939","volume":"6","author":"C Pellegrini","year":"2015","unstructured":"Pellegrini, C. et al. All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype. Oncotarget 6, 29914\u201329928. https:\/\/doi.org\/10.18632\/oncotarget.4939 (2015).","journal-title":"Oncotarget"},{"key":"80837_CR39","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1073\/pnas.1802811115","volume":"115","author":"AJ DuBose","year":"2018","unstructured":"DuBose, A. J. et al. Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts. Proc. Natl. Acad. Sci. USA 115, 4206\u20134211. https:\/\/doi.org\/10.1073\/pnas.1802811115 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"80837_CR40","doi-asserted-by":"publisher","first-page":"119","DOI":"10.18632\/aging.100434","volume":"4","author":"MK Driscoll","year":"2012","unstructured":"Driscoll, M. K. et al. Automated image analysis of nuclear shape: What can we learn from a prematurely aged cell?. Aging (Albany NY) 4, 119\u2013132. https:\/\/doi.org\/10.18632\/aging.100434 (2012).","journal-title":"Aging (Albany NY)"},{"key":"80837_CR41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10137","volume":"474","author":"S Dupont","year":"2011","unstructured":"Dupont, S. et al. Role of YAP\/TAZ in mechanotransduction. Nature 474, 179\u2013183. https:\/\/doi.org\/10.1038\/nature10137 (2011).","journal-title":"Nature"},{"key":"80837_CR42","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/978-1-4899-8032-8_20","volume":"773","author":"C Denais","year":"2014","unstructured":"Denais, C. & Lammerding, J. Nuclear mechanics in cancer. Adv. Exp. Med. Biol. 773, 435\u2013470. https:\/\/doi.org\/10.1007\/978-1-4899-8032-8_20 (2014).","journal-title":"Adv. Exp. Med. Biol."},{"key":"80837_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101893","volume":"41","author":"Y Ou","year":"2024","unstructured":"Ou, Y., Wang, M., Xu, Q., Sun, B. & Jia, Y. Small molecule agents for triple negative breast cancer: Current status and future prospects. Transl. Oncol. 41, 101893. https:\/\/doi.org\/10.1016\/j.tranon.2024.101893 (2024).","journal-title":"Transl. Oncol."},{"key":"80837_CR44","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni.3558","volume":"17","author":"Q Chen","year":"2016","unstructured":"Chen, Q., Sun, L. & Chen, Z. J. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat. Immunol. 17, 1142\u20131149. https:\/\/doi.org\/10.1038\/ni.3558 (2016).","journal-title":"Nat. Immunol."},{"key":"80837_CR45","doi-asserted-by":"publisher","unstructured":"Zink, D., Fischer, A. H., Nickerson, J. A. Nuclear structure in cancer cells. Nat Rev Cancer. 4, 677\u2013687. https:\/\/doi.org\/10.1038\/nrc1430 (2004).","DOI":"10.1038\/nrc1430"},{"key":"80837_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/JOC.JOC_237_16","volume":"35","author":"A Kashyap","year":"2018","unstructured":"Kashyap, A., Jain, M., Shukla, S. & Andley, M. Role of nuclear morphometry in breast cancer and its correlation with cytomorphological grading of breast cancer: A study of 64 cases. J. Cytol. 35, 41\u201345. https:\/\/doi.org\/10.4103\/JOC.JOC_237_16 (2018).","journal-title":"J. Cytol."},{"key":"80837_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/19491034.2017.1414118","volume":"9","author":"AD Stephens","year":"2018","unstructured":"Stephens, A. D., Banigan, E. J. & Marko, J. F. Separate roles for chromatin and lamins in nuclear mechanics. Nucleus 9, 119\u2013124. https:\/\/doi.org\/10.1080\/19491034.2017.1414118 (2018).","journal-title":"Nucleus"},{"key":"80837_CR48","doi-asserted-by":"publisher","first-page":"ar45","DOI":"10.1091\/mbc.E21-10-0528","volume":"33","author":"KR Atanasova","year":"2022","unstructured":"Atanasova, K. R. et al. An epigenetic small molecule screen to target abnormal nuclear morphology in human cells. Mol. Biol. Cell 33, ar45. https:\/\/doi.org\/10.1091\/mbc.E21-10-0528 (2022).","journal-title":"Mol. Biol. Cell"},{"key":"80837_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.374","volume":"7","author":"S Blondel","year":"2016","unstructured":"Blondel, S. et al. Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation. Cell Death Dis. 7, e2105. https:\/\/doi.org\/10.1038\/cddis.2015.374 (2016).","journal-title":"Cell Death Dis."},{"key":"80837_CR50","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ymeth.2015.08.024","volume":"96","author":"N Kubben","year":"2016","unstructured":"Kubben, N., Brimacombe, K. R., Donegan, M., Li, Z. & Misteli, T. A high-content imaging-based screening pipeline for the systematic identification of anti-progeroid compounds. Methods 96, 46\u201358. https:\/\/doi.org\/10.1016\/j.ymeth.2015.08.024 (2016).","journal-title":"Methods"},{"key":"80837_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/g3journal\/jkab264","author":"R Maheshwari","year":"2021","unstructured":"Maheshwari, R., Rahman, M. M., Joseph-Strauss, D. & Cohen-Fix, O. An RNAi screen for genes that affect nuclear morphology in Caenorhabditis elegans reveals the involvement of unexpected processes. G3 (Bethesda). https:\/\/doi.org\/10.1093\/g3journal\/jkab264 (2021).","journal-title":"G3 (Bethesda)."},{"key":"80837_CR52","doi-asserted-by":"publisher","unstructured":"Breusegem, S. Y. et al. A multiparametric anti-aging CRISPR screen uncovers a role for BAF in protein translation. bioRxiv. 2022.2010.2007.509469. https:\/\/doi.org\/10.1101\/2022.10.07.509469 (2022).","DOI":"10.1101\/2022.10.07.509469"},{"key":"80837_CR53","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/j.1365-2133.2009.09106.x","volume":"160","author":"J Bourke","year":"2009","unstructured":"Bourke, J., Coulson, I., English, J., British Association of Dermatologists Therapy, G. & Audit, S. Guidelines for the management of contact dermatitis: An update. Br. J. Dermatol. 160, 946\u2013954. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09106.x (2009).","journal-title":"Br. J. Dermatol."},{"key":"80837_CR54","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1080\/10245332.2018.1436395","volume":"23","author":"X Wang","year":"2018","unstructured":"Wang, X., Shi, J. & Gong, D. Mometasone furoate inhibits growth of acute leukemia cells in childhood by regulating PI3K signaling pathway. Hematology 23, 478\u2013485. https:\/\/doi.org\/10.1080\/10245332.2018.1436395 (2018).","journal-title":"Hematology"},{"key":"80837_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11102597","author":"L Qiu","year":"2023","unstructured":"Qiu, L., Gao, Q., Tao, A., Jiang, J. & Li, C. Mometasone furoate inhibits the progression of head and neck squamous cell carcinoma via regulating protein tyrosine phosphatase non-receptor type 11. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11102597 (2023).","journal-title":"Biomedicines."},{"key":"80837_CR56","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1242\/jcs.02429","volume":"118","author":"V Shahin","year":"2005","unstructured":"Shahin, V., Ludwig, Y., Schafer, C., Nikova, D. & Oberleithner, H. Glucocorticoids remodel nuclear envelope structure and permeability. J. Cell Sci. 118, 2881\u20132889. https:\/\/doi.org\/10.1242\/jcs.02429 (2005).","journal-title":"J. Cell Sci."},{"key":"80837_CR57","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix, U. et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110, 4055\u20134063. https:\/\/doi.org\/10.1182\/blood-2007-07-102061 (2007).","journal-title":"Blood"},{"key":"80837_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030917","author":"A Rodriguez-Agustin","year":"2023","unstructured":"Rodriguez-Agustin, A. et al. Immunomodulatory activity of the tyrosine kinase inhibitor dasatinib to elicit NK cytotoxicity against cancer, HIV infection and aging. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15030917 (2023).","journal-title":"Pharmaceutics."},{"key":"80837_CR59","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167270","author":"W Dunker","year":"2023","unstructured":"Dunker, W. et al. The proto-oncogene SRC phosphorylates cGAS to inhibit an antitumor immune response. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.167270 (2023).","journal-title":"JCI Insight."},{"key":"80837_CR60","doi-asserted-by":"publisher","first-page":"300060519877321","DOI":"10.1177\/0300060519877321","volume":"48","author":"X Wei","year":"2020","unstructured":"Wei, X., He, L., Wang, X., Lin, M. & Dai, J. Effects of dasatinib on CD8(+)T, Th1, and Treg cells in patients with chronic myeloid leukemia. J. Int. Med. Res. 48, 300060519877321. https:\/\/doi.org\/10.1177\/0300060519877321 (2020).","journal-title":"J. Int. Med. Res."},{"key":"80837_CR61","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.259493","author":"SB Lavenus","year":"2022","unstructured":"Lavenus, S. B. et al. Emerin regulation of nuclear stiffness is required for fast amoeboid migration in confined environments. J. Cell Sci. https:\/\/doi.org\/10.1242\/jcs.259493 (2022).","journal-title":"J. Cell Sci."},{"key":"80837_CR62","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou, C. et al. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 9, 722\u2013737. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1218 (2019).","journal-title":"Cancer Discov."},{"key":"80837_CR63","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding, L. et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 25, 2972-2980.e2975. https:\/\/doi.org\/10.1016\/j.celrep.2018.11.054 (2018).","journal-title":"Cell Rep."},{"key":"80837_CR64","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1002\/1878-0261.12573","volume":"13","author":"PM Schoonen","year":"2019","unstructured":"Schoonen, P. M. et al. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells. Mol. Oncol. 13, 2422\u20132440. https:\/\/doi.org\/10.1002\/1878-0261.12573 (2019).","journal-title":"Mol. Oncol."},{"key":"80837_CR65","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/1535-7163.MCT-07-2391","volume":"7","author":"A Blasina","year":"2008","unstructured":"Blasina, A. et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol. Cancer Ther. 7, 2394\u20132404. https:\/\/doi.org\/10.1158\/1535-7163.MCT-07-2391 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"80837_CR66","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1158\/1078-0432.CCR-08-3272","volume":"15","author":"C Zhang","year":"2009","unstructured":"Zhang, C. et al. PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts. Clin. Cancer Res. 15, 4630\u20134640. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-3272 (2009).","journal-title":"Clin. Cancer Res."},{"key":"80837_CR67","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.4161\/cc.20899","volume":"11","author":"L Carrassa","year":"2012","unstructured":"Carrassa, L. et al. Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle 11, 2507\u20132517. https:\/\/doi.org\/10.4161\/cc.20899 (2012).","journal-title":"Cell Cycle"},{"key":"80837_CR68","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-015-0206-5","volume":"8","author":"I Iacobucci","year":"2015","unstructured":"Iacobucci, I. et al. In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. J. Hematol. Oncol. 8, 125. https:\/\/doi.org\/10.1186\/s13045-015-0206-5 (2015).","journal-title":"J. Hematol. Oncol."},{"key":"80837_CR69","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1101\/gad.14.12.1448","volume":"14","author":"Q Liu","year":"2000","unstructured":"Liu, Q. et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)\/M DNA damage checkpoint. Genes Dev. 14, 1448\u20131459 (2000).","journal-title":"Genes Dev."},{"key":"80837_CR70","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/ijc.33918","volume":"150","author":"C Zong","year":"2022","unstructured":"Zong, C. et al. PARP mediated DNA damage response, genomic stability and immune responses. Int. J. Cancer 150, 1745\u20131759. https:\/\/doi.org\/10.1002\/ijc.33918 (2022).","journal-title":"Int. J. Cancer"},{"key":"80837_CR71","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","volume":"163","author":"PD Shah","year":"2021","unstructured":"Shah, P. D. et al. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol. Oncol. 163, 246\u2013253. https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.024 (2021).","journal-title":"Gynecol. Oncol."},{"key":"80837_CR72","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1158\/1078-0432.CCR-23-1696","volume":"29","author":"A Ring","year":"2023","unstructured":"Ring, A. et al. Olaparib and ceralasertib (AZD6738) in patients with triple-negative advanced breast cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK\/15\/010). Clin. Cancer Res. 29, 4751\u20134759. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1696 (2023).","journal-title":"Clin. Cancer Res."},{"key":"80837_CR73","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","volume":"29","author":"SL Wethington","year":"2023","unstructured":"Wethington, S. L. et al. Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer. Clin. Cancer Res. 29, 2800\u20132807. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2444 (2023).","journal-title":"Clin. Cancer Res."},{"key":"80837_CR74","doi-asserted-by":"publisher","first-page":"22659","DOI":"10.1038\/s41598-023-50151-y","volume":"13","author":"L Biegala","year":"2023","unstructured":"Biegala, L. et al. Targeted inhibition of the ATR\/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2(MUT) ovarian cancer cells. Sci. Rep. 13, 22659. https:\/\/doi.org\/10.1038\/s41598-023-50151-y (2023).","journal-title":"Sci. Rep."},{"key":"80837_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10020121","author":"BT Burgess","year":"2020","unstructured":"Burgess, B. T. et al. Olaparib combined with an ATR or Chk1 inhibitor as a treatment strategy for acquired olaparib-resistant BRCA1 mutant ovarian cells. Diagnostics (Basel). https:\/\/doi.org\/10.3390\/diagnostics10020121 (2020).","journal-title":"Diagnostics (Basel)."},{"key":"80837_CR76","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim, H. et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat. Commun. 11, 3726. https:\/\/doi.org\/10.1038\/s41467-020-17127-2 (2020).","journal-title":"Nat. Commun."},{"key":"80837_CR77","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","volume":"9","author":"T Sen","year":"2019","unstructured":"Sen, T. et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 9, 646\u2013661. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1020 (2019).","journal-title":"Cancer Discov."},{"key":"80837_CR78","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.jtho.2019.08.009","volume":"14","author":"T Sen","year":"2019","unstructured":"Sen, T. et al. Combination treatment of the oral CHK1 inhibitor, SRA737, and low-dose gemcitabine enhances the effect of programmed death ligand 1 blockade by modulating the immune microenvironment in SCLC. J. Thorac. Oncol. 14, 2152\u20132163. https:\/\/doi.org\/10.1016\/j.jtho.2019.08.009 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"80837_CR79","doi-asserted-by":"publisher","first-page":"6717","DOI":"10.1158\/0008-5472.CAN-18-2652","volume":"78","author":"RA Stewart","year":"2018","unstructured":"Stewart, R. A., Pilie, P. G. & Yap, T. A. Development of PARP and immune-checkpoint inhibitor combinations. Cancer Res. 78, 6717\u20136725. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-2652 (2018).","journal-title":"Cancer Res."},{"key":"80837_CR80","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1158\/0008-5472.CAN-20-3738","volume":"81","author":"B Wei","year":"2021","unstructured":"Wei, B. et al. SHP2-mediated inhibition of DNA repair contributes to cGAS-STING activation and chemotherapeutic sensitivity in colon cancer. Cancer Res. 81, 3215\u20133228. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3738 (2021).","journal-title":"Cancer Res."},{"key":"80837_CR81","doi-asserted-by":"publisher","first-page":"89ra58","DOI":"10.1126\/scitranslmed.3002346","volume":"3","author":"K Cao","year":"2011","unstructured":"Cao, K. et al. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci. Transl. Med. 3, 89ra58. https:\/\/doi.org\/10.1126\/scitranslmed.3002346 (2011).","journal-title":"Sci. Transl. Med."},{"key":"80837_CR82","doi-asserted-by":"publisher","first-page":"5032","DOI":"10.1038\/s41598-023-32035-3","volume":"13","author":"NO Abutaleb","year":"2023","unstructured":"Abutaleb, N. O. et al. Lonafarnib and everolimus reduce pathology in iPSC-derived tissue engineered blood vessel model of Hutchinson-Gilford Progeria Syndrome. Sci. Rep. 13, 5032. https:\/\/doi.org\/10.1038\/s41598-023-32035-3 (2023).","journal-title":"Sci. Rep."},{"key":"80837_CR83","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1042\/EBC20190007","volume":"63","author":"CR Pfeifer","year":"2019","unstructured":"Pfeifer, C. R., Vashisth, M., Xia, Y. & Discher, D. E. Nuclear failure, DNA damage, and cell cycle disruption after migration through small pores: A brief review. Essays Biochem. 63, 569\u2013577. https:\/\/doi.org\/10.1042\/EBC20190007 (2019).","journal-title":"Essays Biochem."},{"key":"80837_CR84","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1083\/jcb.201711161","volume":"217","author":"Y Xia","year":"2018","unstructured":"Xia, Y. et al. Nuclear rupture at sites of high curvature compromises retention of DNA repair factors. J. Cell Biol. 217, 3796\u20133808. https:\/\/doi.org\/10.1083\/jcb.201711161 (2018).","journal-title":"J. Cell Biol."},{"key":"80837_CR85","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.260753","author":"BH Hayes","year":"2023","unstructured":"Hayes, B. H. et al. Confinement plus myosin-II suppression maximizes heritable loss of chromosomes, as revealed by live-cell ChReporters. J. Cell Sci. https:\/\/doi.org\/10.1242\/jcs.260753 (2023).","journal-title":"J. Cell Sci."},{"key":"80837_CR86","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202205051","author":"M Dantas","year":"2022","unstructured":"Dantas, M., Oliveira, A., Aguiar, P., Maiato, H. & Ferreira, J. G. Nuclear tension controls mitotic entry by regulating cyclin B1 nuclear translocation. J. Cell Biol. https:\/\/doi.org\/10.1083\/jcb.202205051 (2022).","journal-title":"J. Cell Biol."},{"key":"80837_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-022-01431-x","author":"E Frittoli","year":"2022","unstructured":"Frittoli, E. et al. Tissue fluidification promotes a cGAS-STING cytosolic DNA response in invasive breast cancer. Nat. Mater. https:\/\/doi.org\/10.1038\/s41563-022-01431-x (2022).","journal-title":"Nat. Mater."},{"key":"80837_CR88","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1021\/acschembio.2c00004","volume":"17","author":"S Tollis","year":"2022","unstructured":"Tollis, S. et al. Chemical interrogation of nuclear size identifies compounds with cancer cell line-specific effects on migration and invasion. ACS Chem. Biol. 17, 680\u2013700. https:\/\/doi.org\/10.1021\/acschembio.2c00004 (2022).","journal-title":"ACS Chem. Biol."},{"key":"80837_CR89","doi-asserted-by":"crossref","unstructured":"Zhang, X. Optimal High-Throughput Screening: Practical Experimental Design and Data Analysis for Genome-Scale RNAi Research. (2011).","DOI":"10.1017\/CBO9780511973888"},{"key":"80837_CR90","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.bbrc.2008.07.078","volume":"374","author":"QS Li","year":"2008","unstructured":"Li, Q. S., Lee, G. Y., Ong, C. N. & Lim, C. T. AFM indentation study of breast cancer cells. Biochem. Biophys. Res. Commun. 374, 609\u2013613. https:\/\/doi.org\/10.1016\/j.bbrc.2008.07.078 (2008).","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80837-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80837-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80837-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T14:03:59Z","timestamp":1735394639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80837-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["80837"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-80837-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"30 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30786"}}